By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Dextran 40 (monograph) > Dextran, Low Molecular Weight Dosage
Drugs
https://themeditary.com/dosage-information/dextran-low-molecular-weight-dosage-2307.html

Dextran, Low Molecular Weight Dosage

Drug Detail:Dextran 40 (monograph) (Medically reviewed)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Shock

Initial dose: 20 mL/kg IV during the first 24 hours
Maintenance dose: 10 mL/kg IV per day
Maximum dose: 20 mL/kg IV per day
Duration of therapy: Should therapy continue beyond 24 hours, subsequent doses should not exceed 10 mL/kg IV per day and therapy should not continue beyond 5 days.

Comments:

  • The first 10 mL/kg IV may be infused as rapidly as necessary to result in improvement.
  • Monitor central venous pressure frequently during the initial infusion.

Use: For use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery, or other trauma (this drug is not indicated as a replacement for whole blood or blood components if they are available and it should not replace other forms of therapy known to be of value in the treatment of shock)

Usual Adult Dose for Deep Vein Thrombosis

Initial dose: 10 to 20 mL of a 10% solution (1 to 2 g) per kg are added to the perfusion circuit
Maximum dose: 2 g/kg IV

Comments:

  • The dose of this drug will vary with the volume of the pump oxygenator.
  • This drug can serve as a sole primer or as an additive to other priming fluids.

Use: For use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation

Usual Adult Dose for Pulmonary Thromboembolism

Initial dose: 10 to 20 mL of a 10% solution (1 to 2 g) per kg are added to the perfusion circuit
Maximum dose: 2 g/kg IV

Comments:

  • The dose of this drug will vary with the volume of the pump oxygenator.
  • This drug can serve as a sole primer or as an additive to other priming fluids.

Use: For use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation

Usual Adult Dose for Venous Thromboembolism

Initial dose: 500 to 1000 mL (approximately 10 mL/kg) IV administered on the day of operation
Maintenance dose: 500 mL daily IV for an additional 2 to 3 days, then according to the risk of complications, 500 mL IV may be given every second or third day during the period of risk
Duration of therapy: Up to 2 weeks

Comment:

  • The dose of this drug should be chosen according to the risk of thromboembolic complications.

Use: For use in prophylaxis of venous thrombosis and pulmonary embolism in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications (e.g., hip surgery)

Usual Pediatric Dose for Shock

1 month to less than 12 months:
5 mL/kg IV

1 year to adolescent:
10 mL/kg IV

Adolescents:
Initial dose: 20 mL/kg IV during the first 24 hours
Maintenance dose: 10 mL/kg IV per day
Maximum dose: 20 mL/kg IV per day
Duration of therapy: Should therapy continue beyond 24 hours, subsequent doses should not exceed 10 mL/kg per day and therapy should not continue beyond 5 days.

Comments:

  • The first 10 mL/kg IV may be infused as rapidly as necessary to result in improvement.
  • Monitor central venous pressure frequently during the initial infusion.

Use: For use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery, or other trauma (this drug is not indicated as a replacement for whole blood or blood components if they are available and it should not replace other forms of therapy known to be of value in the treatment of shock)

Usual Pediatric Dose for Deep Vein Thrombosis

1 month to less than 12 months:
5 mL/kg IV

1 year to adolescent:
10 mL/kg IV

Adolescents:
Initial dose: 10 to 20 mL of a 10% solution (1 to 2 g) per kg are added to the perfusion circuit
Maximum dose: 2 g/kg IV

Comments:

  • The dose of this drug will vary with the volume of the pump oxygenator.
  • This drug can serve as a sole primer or as an additive to other priming fluids.

Use: For use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation

Usual Pediatric Dose for Pulmonary Embolism

1 month to less than 12 months:
5 mL/kg IV

1 year to adolescent:
10 mL/kg IV

Adolescents:
Initial dose: 10 to 20 mL of a 10% solution (1 to 2 g) per kg are added to the perfusion circuit
Maximum dose: 2 g/kg IV

Comments:

  • The dose of this drug will vary with the volume of the pump oxygenator.
  • This drug can serve as a sole primer or as an additive to other priming fluids.

Use: For use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation

Usual Pediatric Dose for Venous Thromboembolism

1 month to less than 12 months:
5 mL/kg IV

1 year to adolescent:
10 mL/kg IV

Initial dose: 500 to 1000 mL (approximately 10 mL/kg) IV administered on the day of operation
Maintenance dose: 500 mL daily IV for an additional 2 to 3 days, then according to the risk of complications, 500 mL IV may be given every second or third day during the period of risk
Duration of therapy: Up to 2 weeks

Comment:

  • The dose of this drug should be chosen according to the risk of thromboembolic complications.

Use: For use in prophylaxis of venous thrombosis and pulmonary embolism in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications (e.g., hip surgery)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or any of the ingredients
  • In patients with marked hemostatic defects of all types (e.g., thrombocytopenia, hypofibrinogenemia) including those caused by drugs (e.g., heparin, warfarin)
  • Marked cardiac decompensation
  • Renal disease with severe oliguria or anuria

Safety and efficacy have not been established in patients younger than 1 month.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Administer by intravenous (IV) infusion only
  • Administration set should include a filter
  • Do not use if crystallization has occurred

Storage requirements:
  • Store at 20C to 25C (68F to 77F).
  • Protect from freezing.

Reconstitution/preparation techniques:
  • To open tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect solution quality or safety. The opacity will diminish gradually.
  • Use aseptic technique:
1) Close flow control clamp of administration set.
2) Remove cover from outlet port at bottom of container.
3) Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. Note: See full directions on administration set carton.
4) Suspend container from hanger.
5) Squeeze and release drip chamber to establish proper fluid level in drip chamber.
6) Open flow control clamp and clear air from set. Close clamp.
7) Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
8) Regulate rate of administration with flow control clamp.
  • WARNING: Do not use flexible container in series connections.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by